NCT00847210View on ClinicalTrials.gov

Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Gastroesophageal Reflux
Interventions
DRUG

Dexlansoprazole MR

Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to 7 days.

DRUG

Dexlansoprazole MR

Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 7 days.

Trial Locations (3)

Unknown

Anaheim

Cypress

Overland Park

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT00847210 - Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease | Biotech Hunter | Biotech Hunter